MARKET WIREYahoo • 2d ago
BioArctic's Nomination Committee appointedBioArctic AB (publ) (Nasdaq Stockholm: BIOA B) today announced the composition of its Nomination Committee for the 2027 Annual General Meeting.
Why BIOA Stock Traded Steady Today — RQD Quant Desk Flash
$5.94 0.00% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $5.93
BioAge Labs Inc. (BIOA) carries a Roarable Rating of D (Sell) with 44/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D • SELL / AVOID
Cap $272.6M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on BIOA Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is BIOA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-01, BioAge Labs Inc. (NASDAQ: BIOA) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $5.94 (0.00% 1D, market cap $272.6M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, BIOA ranks #511 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does BIOA compare to LYEL and LRMR in the Health Care sector?
▼
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BIOA carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, LYEL (Lyell Immunopharma Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $277.0M) and LRMR (Larimar Therapeutics Inc.) posts a D grade (50/100 RQD, P/E N/A, ROIC -35.0%, cap $277.4M). Among the 5-stock peer group, BIOA leads on earnings multiple (N/A) while BIOA leads on capital efficiency (-35.0% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for BIOA?
▼
Per BIOA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001709941), BioAge Labs Inc. generated $9.0M in revenue, -$80.6M in net income, and -$82.3M in free cash flow against $294.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $5.93 (-0.19%)🧬 Dilution Drag (+1.28% YoY Shares)⚙️ Cash Engine: 6/20 (E) • 0% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record Warning: Scores below 50 (44/100 · D) historically underperformed SPY in 71% of rolling 90-day windows (-6.5% avg 90D alpha vs SPY • 29.0% hit rate).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D
2-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw E · Rk C
Each axis scored 0–20
12M PRICE TARGET CONE-6.2% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for BIOA)Realized 20D OHLCV Swing Band: ±12.5%
Deterministic 5-Pillar Attribution (44/100 Composite)
🔍 WHY BIOA SCORES 44/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Macro Regime Fit+15/20 pts (34% of score)
FRED Regime × Technicals: 5% of 52W Range • RSI-14 at 43.4 (NEUTRAL RANGE)
▲ #2 Bullish Driver: SEC 10-K Forensic Risk+11/20 pts (25% of score)
Altman Z-Score 5.66 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 2/9
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)
Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade C-$6.34-23.7% Next Q
52
Q2 (-2Q)Grade D$4.84+5.4% Next Q
49
Q3 (-1Q)Grade D$5.10+16.5% Next Q
47
CurrentGrade D$5.94-6.5% Hist 90D α
44
Trajectory: C- (52) → D (44)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a BIOA Turnaround Squeeze
While BIOA currently carries a cautious 44/100 (D) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Health Care with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($7.39) and Max Pain ($6.24) forces dealer call-delta covering toward $27.26.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $BIOA• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “BIOA Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why BIOA Stock Traded Steady Today — RQD Quant Desk Flash
BioAge Labs Inc. (BIOA) slipped 0.00% to $5.94, trading at 5% of its 52-week range ($4.81 – $25.96). Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 5% of its 52-week range ($4.81 – $25.96) with RSI-14 at 43.4 (NEUTRAL RANGE).
- ▸Volatility Profile: Historical 20-day realized swing band of ±12.5% around $5.94 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D (Sell) backed by 52% gross margin and $0 annual free cash flow.
Live BIOA Headlines & Catalysts
CATALYSTYahoo • 3d ago
Earnings Preview: BioAge Labs, Inc. (BIOA) Q3 Earnings Expected to DeclineBioAge Labs, Inc. (BIOA) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BIOA)
- ✓Walkthrough of BIOA's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
BIOA // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -64.75%🛡️ HOLDING TREND SUPPORT
2026-10-30O $5.87H $5.94L $5.63C $5.94VOL 801.3K
RES: $31.70SUP: $4.10SMA50: $7.39SMA200: $15.82
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
BIOA Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. +6.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on BIOA today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for BIOA. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for BIOA today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BIOA)
Health Care Rank #511 of 1016
⚔️ LYEL vs BIOA Full Matrix →
1. Head-to-Head Health Care Peer Comparison (BIOA vs. LYEL, LRMR, BCYC, RCKT)
Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)Across 1016 tracked Health Care securities in the Roarable RQD universe, BioAge Labs Inc. (BIOA) ranks #511 by composite RQD confidence (44/100, grade D) and #532 by equity capitalization ($272.6M). Within this direct 5-issuer industry benchmark cohort, BIOA leads on earnings valuation at N/A trailing P/E, while BIOA leads on capital efficiency and profitability with -35.0% ROIC and — gross margin. LRMR currently holds the highest overall quantitative score in the immediate peer group at 50/100 (D) compared with BIOA at 44/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| BIOA
ACTIVE
BioAge Labs Inc. | D | 44/100 | — | — | -35.0% | 0.00% | $272.6M | Benchmark Subject |
| LYEL Lyell Immunopharma Inc. | D- | 38/100 | — | — | -35.0% | +3.43% | $277.0M | /lyel-vs-bioa → |
| LRMR Larimar Therapeutics Inc. | D | 50/100 | — | — | -35.0% | +5.12% | $277.4M | /lrmr-vs-bioa → |
| BCYC Bicycle Therapeutics plc | E | 24/100 | — | — | -35.0% | -1.55% | $267.4M | /bcyc-vs-bioa → |
| RCKT Rocket Pharmaceuticals Inc. | E | 31/100 | — | — | -35.0% | -1.55% | $278.8M | /rckt-vs-bioa → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001709941In its most recent audited fiscal period (FY2025, filed 2025-12-31), BioAge Labs Inc. (BIOA) reported GAAP revenue of $9.0M (N/A vs. FY2024 revenue of $0 ) , GAAP net income of -$80.6M, operating cash flow of -$81.6M, and free cash flow of -$82.3M (-58.7% YoY). On the balance sheet, BIOA closed FY2025 with $294.9M in total assets against $0 in total debt (Altman Z-Score: 5.66, Piotroski F-Score: 2/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $9.0M | -$80.6M | -$81.6M | -$82.3M | $294.9M | $0 |
| FY2024 (FY) | 2024-12-31 | $0 | -$71.1M | -$51.5M | -$51.9M | $358.2M | $2.5M |
| FY2023 (FY) | 2023-12-31 | $0 | -$63.9M | -$37.4M | -$37.4M | — | — |
3. BIOA Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs BIOA stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-01, BioAge Labs Inc. (NASDAQ: BIOA) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 44/100 at a spot price of $5.94 (0.00% 1D, market cap $272.6M). Pillar breakdown: Fundamental Cash Engine 6/20, Institutional 13F & Options Flow 9/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, BIOA ranks #511 in composite RQD confidence.
How does BIOA compare to LYEL and LRMR in the Health Care sector?
Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), BIOA carries a Roarable D (44/100 RQD), trailing P/E of N/A, gross margin of —, and ROIC of -35.0%. By comparison, LYEL (Lyell Immunopharma Inc.) holds a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $277.0M) and LRMR (Larimar Therapeutics Inc.) posts a D grade (50/100 RQD, P/E N/A, ROIC -35.0%, cap $277.4M). Among the 5-stock peer group, BIOA leads on earnings multiple (N/A) while BIOA leads on capital efficiency (-35.0% ROIC).
What are the biggest fundamental strengths and SEC risk factors for BIOA?
Per BIOA's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001709941), BioAge Labs Inc. generated $9.0M in revenue, -$80.6M in net income, and -$82.3M in free cash flow against $294.9M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is BIOA trading relative to its 50-day, 200-day, and 52-week technical levels?
BIOA last traded at $5.94 (0.00% on volume of 845,276 shares), positioning the stock -19.62% below its 50-day simple moving average ($7.39) and -62.45% below its 200-day simple moving average ($15.82). Across its 52-week range of $4.81 to $25.96, BIOA sits at the 5.3% percentile with a 14-day RSI of 43.4 (NEUTRAL RANGE) and an implied next-earnings move of ±12.5% ($5.20 to $6.68).
BIOA Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is BIOA stock moving today?
Why BIOA Stock Traded Steady Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-35% return on capital) under elevated 10-year interest-rate pressure.